ReviewThe Lancet. Microbe2024
Staphylococcus aureus colonisation and strategies for decolonisation.
Review in The Lancet. Microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 126 citations in OpenAlex.
- Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BB.Nature communications · 2025Trial
- Antibacterial and Antibiofilm Activity ofJournal of fungi (Basel, Switzerland) · 2026Article
- Antimicrobial-resistant Staphylococcus aureus isolated from Australian wildlife admitted to a veterinary hospital.Australian veterinary journal · 2026Article
- A Practical Dermatology Focused Approach to Staphylococcus aureus Decolonisation in Children.The Australasian journal of dermatology · 2026Article
- Differential Roles of Ag and ZnO in the Bactericidal Activity of Ag/ZnO-Hydroxyapatite Nanocomposites against Multidrug-Associated Methicillin-Resistant Staphylococcus aureus.Current microbiology · 2026Article
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- ABPs: diffusible antibacterial toxins secreted by and active against diverse gram-positive bacteria.Infection and immunity · 2026Review
- Genomic diversity and topical antimicrobial resistance inAntimicrobial agents and chemotherapy · 2026Article
- Dental clinic surfaces as reservoirs of biofilm-forming Staphylococcus aureus and Enterococcus spp. isolates: phenotypic and genotypic analysis.Molecular biology reports · 2026Article
- Candida albicans activates Staphylococcus aureus virulence regulatory systems to drive toxin-mediated human cell death.PLoS pathogens · 2026Article
- Two Novel 1,4-Naphthoquinone Derivatives as Potent Agents Against Multidrug-Resistant Staphylococcus aureus and Pathogenic Gram-Positive Bacteria.Drug development research · 2026Article
- Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Biofilm sensitization to breakJournal of medical microbiology · 2026Article
- Article
- N-sulfonylated indole hydrazone hybrid targeting Staphylococcus aureus with compelling antibiofilm and membrane-disrupting properties.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- MRSA carriage rate among dental healthcare personnel: amulticentric cross-sectional study.Acta odontologica latinoamericana : AOL · 2026Article
- ThebioRxiv : the preprint server for biology · 2026Article
- Article
- A composite medium enabling co-culture ofMethodsX · 2026Article
- The Scorpion Peptide Derivative HP-H1K8 is a Promising Topical Agent Against Methicillin-Resistant Staphylococcus Aureus.Probiotics and antimicrobial proteins · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Staphylococcus aureus is a leading cause of death by infectious diseases worldwide. Treatment of S aureus infections is difficult due to widespread antibiotic resistance, necessitating alternative approaches and measures for prevention of infection. Because S aureus infections commonly arise from asymptomatic colonisation, decolonisation is considered a key approach for their prevention. Current decolonisation procedures include antibiotic-based and antiseptic-based eradication of S aureus from the nose and skin. However, despite the widespread implementation and partial success of such measures, S aureus infection rates remain worrisome, and resistance to decolonisation agents is on the rise. In this Review we outline the epidemiology and mechanisms of S aureus colonisation, describe how colonisation underlies infection, and discuss current and novel approaches for S aureus decolonisation, with a focus on the latest findings on probiotic strategies and the intestinal S aureus colonisation site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.